Arvinas (ARVN) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need For Additional Capital

1. 01We have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability
2. 02We have never generated revenue from product sales and may never be profitable
3. 03We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
5. 05Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability
6. 06Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition
7. 07In the future, we might not be able to utilize a significant portion of any net operating loss carryforwards and research and development tax credit carryforwards we may have
8. 08carryforwards may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of our taxable income in the year in which carryforwards are used

Risks Related to the Discovery and Development of Our Product Candidates

1. 09Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products
2. 10We are early in our development efforts. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed
3. 11Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
4. 12If serious adverse events, undesirable side effects, or unexpected characteristics are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates
5. 13Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
6. 14If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented
7. 15We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
8. 16ARV-393, ARV-102, we may not be able to complete clinical development of vepdegestrant, ARV-393 or ARV-102 on our current timeline or at all
9. 17We plan to conduct clinical trials for our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations
10. 18We may not be successful in our efforts to identify or discover additional potential product candidates
11. 19We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
12. 20For specific information regarding competition to our assets, see “Item 1. Business—Competition” in this Annual Report on Form 10-K

Risks Related to Dependence on Third Parties

1. 21If our collaboration with Pfizer is not successful, we may not be able to capitalize on the market potential of vepdegestrant
2. 22payments based on specified regulatory and sales-based milestones for the Licensed Products under the Vepdegestrant (ARV-471) Collaboration Agreement
3. 23We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials
4. 24Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results

Risks Related to the Commercialization of Our Product Candidates

1. 25Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 26If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved
3. 27Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
4. 28Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop

Risks Related to Our Intellectual Property

1. 29Changes in patent laws or patent jurisprudence could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates
2. 30regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained
3. 31We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors, or other intellectual property, which could be expensive, time-consuming and unsuccessful
4. 32We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all
5. 33Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
6. 34If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business
7. 35We may be subject to claims by third parties asserting that our employees, consultants, contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property
8. 36Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
9. 37Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 38If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
11. 39If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be impaired
12. 40We only have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
13. 41The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed
14. 42preclude our obtaining marketing approval or prevent or limit commercial use. New oncology drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed
15. 43Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed outside of the United States and may limit our ability to generate revenue from product sales
16. 44changes introduced by the Windsor Framework will see the MHRA be responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland
17. 45We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process
18. 46Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight
19. 47The FDA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses
20. 48Similar restrictions apply to the approval of our products in the European Union. The holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products
21. 49notice to residents regarding retention of information. The provisions in the CPRA may apply to some of our business activities
22. 50and the GDPR, respectively. Any changes or updates to these adequacy decisions have the potential to impact our business
23. 51Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain
24. 52The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved
25. 53new law also caps Medicare beneficiaries' out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year
26. 54If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business
27. 55Social media platforms and Artificial Intelligence, or AI, based platforms present new risks and challenges to our business

Risks Related to Employee Matters and Managing Growth

1. 56Our future success depends on our ability to retain key employees, consultants and advisors and to attract, train, retain and motivate qualified personnel
2. 57We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could disrupt our operations
3. 58In addition, we may collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems
4. 59Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could materially harm our business

Risks Related to Our Common Stock

1. 60The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders’ investment
2. 61We may be subject to securities litigation, which is expensive and could divert management attention
3. 62Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to significantly influence or control all matters submitted to stockholders for approval
4. 63Provisions in our organizational documents and under Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
5. 64If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline
6. 65If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well
7. 66In September 2021, we issued 3,457,815 shares of our common stock to Pfizer
8. 67stock could result in higher than average trading volume and may cause the market price for our common stock to decline
9. 68We will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
10. 69Because we have never paid and do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders’ sole source of gain